Disease Spotlight: Prostate Cancer

Catch up on the top radiology content of the past week.

The use of 177Lu-PSMA-617 was associated with a significantly longer radiographic progression-free survival and a 12 percent lower rate of grade 3 or higher adverse events in comparison to a change of ARPI therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).

For patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastasis, the combination of enzalutamide and Ra223 led to a median overall survival rate of 42.3 months in contrast to 35 months for enzalutamide alone, according to research presented at the 2024 European Society for Medical Oncology Congress (ESMO) in Spain.

The PSMA-targeted modality 177Lu-PNT2002 improved radiographic progression-free survival by 29 percent in patients with mCRPC in comparison to ARPI therapy, according to new phase 3 trial data presented at the ESMO Congress in Spain.

For clinically significant prostate cancer, multiparametric MRI (mpMRI) has a pooled sensitivity rate of 88 percent in biopsy-naïve men, according to a new 16-study meta-analysis.

Currently in phase III trials, the 64Cu-SAR-bisPSMA PET agent reportedly offers a longer half-life and higher tumor uptake than other radiopharmaceuticals for prostate cancer imaging.

Catch up on the top radiology content of the past week.

Catch up on the top radiology content of the past week.

Prostate biopsy reclassification was 2.3 times more likely with PI-RADS > 4 lesions in patients in comparison to those with PI-RADS 1-3 lesion assessments, according to new MRI research involving nearly 1,500 men with low-risk and favorable intermediate risk for prostate cancer.

New research revealed an 86 percent AUC for deep learning detection of clinically significant prostate cancer in comparison to 84 percent for four abdominal radiologists with at least 10 years of experience.

Emerging research revealed a median progression-free survival of 16.4 months and a 29-month mean freedom from a new line of systemic therapy for the use of PSMA PET/CT guided, metastasis-targeted radiotherapy for patients with oligometastatic castration-resistant PCa.

Catch up on the top AI-related news and research in radiology over the past month.

Catch up on the most-well viewed radiology content in July 2024.

Catch up on the most-well viewed prostate cancer imaging content in July 2024.

A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.

In comparison to systematic biopsy, researchers found that mpMRI-targeted biopsy had a nine percent higher detection rate for cribriform and intraductal prostate cancer subtypes that are associated with adverse outcomes.

Catch up on the top radiology content of the past week.

The MIM Software HDR Prostate reportedly enables clinicians to utilize preoperative MRI guidance and live ultrasound imaging to enhance tumor visualization during high dose-rate (HDR) brachytherapy treatments for prostate cancer.

For men with prostate cancer, new research demonstrates that 18F-PSMA-1007 PET/CT is 17 percent more accurate than mpMRI at identifying the final pathological tumor stage and 12 percent more accurate in detecting extracapsular extension.

In preliminary research, the targeted alpharadiotherapy agent 225Ac-FL-020 has demonstrated superior antitumor activity in xenograft models and a favorable safety profile.

The combination of deep learning assessment of prostate MRI with PI-RADS classification at a 15 percent risk threshold spared 49 percent of biopsies in comparison to 37 percent employing a PI-RADS>4 only cut-ff approach, according to new research.

Catch up on the most-well viewed radiology content in June 2024.

For patients with oligorecurrent prostate cancer, the use of PSMA PET/CT guidance for metastasis-directed therapy (MDT) provided over 19 months more median progression-free survival than choline PET/CT guidance, according to newly published research.

In comparison to radiologists, new MRI research shows an emerging artificial intelligence (AI) model demonstrated a higher AUROC and a 14.8 percent higher positive predictive value for detecting prostate cancer at a mean PI-RADS 3 or greater operating point.

Catch up on the top radiology content of the past week.

Artificial intelligence (AI) assisted contouring of prostate cancer demonstrated superior balanced accuracy than manual standard-of-care contouring and hemigland contouring with MRI, according to a new study.

Deep transfer learning may elevate the capability of whole-body PET/CT scans to diagnose multiple cancers, ranging from breast cancer and lung cancer to melanoma and prostate cancer, according to new research presented at the SNMMI conference.

In a cohort of 85 patients with biomechanical recurrence of prostate cancer and PSA values less than 2 ng/mL, positive findings on PET imaging with PSMA-18F DCFPyL led to treatment changes in the majority of patients who had negative findings on conventional imaging, according to new research presented at the SNMMI conference.

Catch up on the top radiology content of the past week.

Developed by an extended prostate cancer working group of the European Society of Urogenital Radiology (ESUR), the updated PI-QUAL scoring system emphasizes a simplified scale of image parameters that applies to prostate MRI scans with and without intravenous contrast use.